Defining Primary Refractory Diffuse Large B‐cell Lymphoma (DLBCL) Based on Survival Outcomes
Hematological Oncology · 2023-06 · 41 (S2) · 430-432
DOI: 10.1002/hon.3164_317 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematological Oncology, online erschienen am 09.06.2023. Verfasst von A. M. Bock und 18 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Bock, A. M., Mwangi, R., Wang, Y., Khurana, A., Maurer, M. J., Ayers, A., Kahl, B., Martin, P., Cohen, J., Casulo, C., Lossos, I., Farooq, U., Ayyappan, S., Reicks, T., Habermann, T. M., Flowers, C. R., Cerhan, J. R., Nastoupil, L. J., & Nowakowski, G. S. (2023). Defining Primary Refractory Diffuse Large B‐cell Lymphoma (DLBCL) Based on Survival Outcomes. Hematological Oncology, 41(S2), 430-432. https://doi.org/10.1002/hon.3164_317
Vancouver
Bock AM, Mwangi R, Wang Y, Khurana A, Maurer MJ, Ayers A, et al. Defining Primary Refractory Diffuse Large B‐cell Lymphoma (DLBCL) Based on Survival Outcomes. Hematological Oncology. 2023;41(S2):430-432. doi:10.1002/hon.3164_317
BibTeX
@article{Bock2023,
author = {Bock, A. M. and Mwangi, R. and Wang, Y. and Khurana, A. and Maurer, M. J. and Ayers, A. and Kahl, B. and Martin, P. and Cohen, J. and Casulo, C. and Lossos, I. and Farooq, U. and Ayyappan, S. and Reicks, T. and Habermann, T. M. and Flowers, C. R. and Cerhan, J. R. and Nastoupil, L. J. and Nowakowski, G. S.},
title = {Defining Primary Refractory Diffuse Large B‐cell Lymphoma (DLBCL) Based on Survival Outcomes},
journal = {Hematological Oncology},
year = {2023},
volume = {41},
number = {S2},
pages = {430--432},
doi = {10.1002/hon.3164_317}
}
EUVIMED